Karlheinz Schmelig

Karlheinz Schmelig is a business professional with extensive experience in the biotech and pharmaceutical industries. He currently serves as a Board Observer at Acousia Therapeutics GmbH, a position he has held since 2018.12 Acousia Therapeutics is a German biotech company founded in 2012, focusing on developing novel medicines to combat hearing loss.4

Professional Background

Schmelig's career includes several notable positions:

• Board Member at Tacalyx GmbH (2019 - present)1
• Board Observer at CryoTherapeutics SA (2017 - present)1
• Managing Partner at Creathor Ventures3
• Board Member at Prostatype Genomics2

Education

Karlheinz Schmelig has a strong educational background in business:

• Master of Business Administration (MBA)1
• Bachelor's degree in Business Administration12

Investment Experience

As a Managing Partner at Creathor Ventures, Schmelig has been involved in significant investment decisions in the biotech sector. In 2018, he participated in a €10 million financing round for Acousia Therapeutics, demonstrating his commitment to supporting innovative healthcare solutions.3

Karlheinz Schmelig's LinkedIn username is karlheinz-schmelig-03209b1, as mentioned in the query. His diverse experience in board positions and investments in the biotech industry, particularly in companies focused on novel therapeutics, highlights his expertise in this field.